The University of Chicago Header Logo

Luciana Molinero

TitleRESEARCH ASSOCIATE (ASSISTANT PROFESSOR)
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mhawech-Fauceglia P, McCarthy D, Tonooka A, Scambia G, Garcia Y, Dundr P, Mills AM, Moore K, Sanada S, Bradford L, Stella GC, Bookman M, Sharma SK, Selle F, Molinero L, He Y, Khor V, Landen C, Lin YG. The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 Mar 29; 186:17-25. PMID: 38554625.
      Citations:    Fields:    
    2. Li X, Eastham J, Giltnane JM, Zou W, Zijlstra A, Tabatsky E, Banchereau R, Chang CW, Nabet BY, Patil NS, Molinero L, Chui S, Harryman M, Lau S, Rangell L, Waumans Y, Kockx M, Orlova D, Koeppen H. Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy. J Pathol. 2024 Mar 25. PMID: 38525811.
      Citations:    Fields:    
    3. Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 Oct; 177:20-31. PMID: 37625235; PMCID: PMC10986425.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Landen CN, Molinero L, Hamidi H, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S, Sehouli J. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 05 01; 29(9):1698-1707. PMID: 36595569; PMCID: PMC10150250.
      Citations: 7     Fields:    
    5. Huseni MA, Wang L, Klementowicz JE, Yuen K, Breart B, Orr C, Liu LF, Li Y, Gupta V, Li C, Rishipathak D, Peng J, Senbabaoglu Y, Modrusan Z, Keerthivasan S, Madireddi S, Chen YJ, Fraser EJ, Leng N, Hamidi H, Koeppen H, Ziai J, Hashimoto K, Williams P, McDermott DF, Rosenberg JE, Powles T, Emens LA, Hegde PS, Mellman I, Turley SJ, Wilson MS, Mariathasan S, Molinero L, Merchant M, West NR, Fassò M. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023 01 17; 4(1):100878. PMID: 36599350; PMCID: PMC9873827.
      Citations: 20     Fields:    Translation:AnimalsCells
    6. Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Iwata H, Winer EP, Kockx MM, Peeters D, Chui SY, Lin JC, Nguyen-Duc A, Viale G, Molinero L, Emens LA, Barrios CH, Diéras V. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1733-1743. PMID: 34097070; PMCID: PMC8634452.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    7. Emens LA, Adams S, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P, Barrios CH, Diéras V. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. Ann Oncol. 2021 Dec; 32(12):1650. PMID: 34740469.
      Citations: 4     Fields:    
    8. Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Tan P, Göke J. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Gut. 2022 07; 71(7):1277-1288. PMID: 34433583; PMCID: PMC9185816.
      Citations: 12     Fields:    Translation:HumansAnimals
    9. Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Iwata H, Nechaeva M, Nguyen-Duc A, Chui SY, Husain A, Winer EP, Adams S, Schmid P, Diéras V, Barrios CH. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J Natl Cancer Inst. 2021 08 02; 113(8):1005-1016. PMID: 33523233; PMCID: PMC8328980.
      Citations: 100     Fields:    Translation:HumansCells
    10. Emens LA, Adams S, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P, Barrios CH, Diéras V. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993. Ann Oncol. 2021 Oct; 32(10):1308. PMID: 34353668.
      Citations:    Fields:    
    11. Emens LA, Adams S, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P, Barrios CH, Diéras V. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021 08; 32(8):983-993. PMID: 34272041.
      Citations: 124     Fields:    Translation:Humans
    12. Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021 06 25; 12(1):3969. PMID: 34172722; PMCID: PMC8233428.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    13. Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clin Breast Cancer. 2021 12; 21(6):539-551. PMID: 34154926.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    14. Moore KN, Bookman M, Miller A, Anderson C, Scambia G, Myers T, Robison K, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S, Sehouli J, Taskiran C, Mäenpää J, Garcia Y. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855. PMID: 33891472; PMCID: PMC8189598.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    15. Li Y, Vennapusa B, Chang CW, Tran D, Nakamura R, Sumiyoshi T, Hegde P, Molinero L. Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer. Appl Immunohistochem Mol Morphol. 2021 04 01; 29(4):258-264. PMID: 33030848; PMCID: PMC8132905.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    16. Yoh KE, Lowe CJ, Mahajan S, Suttmann R, Nguy T, Reichelt M, Yang J, Melendez R, Li Y, Molinero L, Ruppel J, Xu W, Plaks V. Enrichment of circulating tumor-derived extracellular vesicles from human plasma. J Immunol Methods. 2021 03; 490:112936. PMID: 33242493.
      Citations: 17     Fields:    Translation:HumansCells
    17. Mittendorf EA, Zhang H, Saji S, Jung KH, Sohn J, Iwata H, Telli ML, Punie K, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N, Barrios CH, Hegg R, Koehler A, Ferrario C, Penault-Llorca F. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020 10 10; 396(10257):1090-1100. PMID: 32966830.
      Citations: 352     Fields:    Translation:HumansCTClinical Trials
    18. Moroney JW, Powderly J, Lieu CH, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637. PMID: 32723836.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    19. Chiang AC, Sequist LVD, Gilbert J, Conkling P, Thompson D, Marcoux JP, Gettinger S, Kowanetz M, Molinero L, O'Hear C, Lam S, Gordon MS, Fassò M. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):455-463.e4. PMID: 32586767.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    20. Schmid P, Rugo HS, Adams S, Schneeweiss A, Iwata H, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Investigators, Barrios CH, Diéras V. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):44-59. PMID: 31786121.
      Citations: 457     Fields:    Translation:HumansCTClinical Trials
    21. Molinero L, Li Y, Chang CW, Maund S, Berg M, Harrison J, O'Hear C, Hegde P, Emens LA, Fassò M. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. J Immunother Cancer. 2019 10 23; 7(1):274. PMID: 31647026; PMCID: PMC6813065.
      Citations: 16     Fields:    Translation:Humans
    22. Hamid O, Molinero L, Bolen CR, Sosman JA, Kluger HM, McDermott DF, Powderly JD, Sarkar I, Ballinger M, O'Hear C, Chen DS, Hegde PS, Hodi FS, Muñoz-Couselo E, Fassò M. Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clin Cancer Res. 2019 10 15; 25(20):6061-6072. PMID: 31358540.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    23. Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, O'Hear C, Lin YG, Emens LA, Fassò M. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322. PMID: 31204078.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    24. Adams S, Molinero L. Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus Nab-Paclitaxel for Metastatic Breast Cancer-In Reply. JAMA Oncol. 2019 06 01; 5(6):908-909. PMID: 30998805.
      Citations:    Fields:    Translation:Humans
    25. Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019 03 01; 5(3):334-342. PMID: 30347025; PMCID: PMC6439843.
      Citations: 114     Fields:    Translation:HumansCTClinical Trials
    26. Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Molinero L, Schmid P, Cassier PA, Fassò M. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 01 01; 5(1):74-82. PMID: 30242306; PMCID: PMC6439773.
      Citations: 325     Fields:    Translation:HumansCTClinical Trials
    27. Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, O'Hear C, Powderly J, Fassò M. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018 11 01; 29(11):2247-2253. PMID: 30219915.
      Citations: 70     Fields:    Translation:HumansCellsCTClinical Trials
    28. IMpassion130 Trial Investigators, Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 11 29; 379(22):2108-2121. PMID: 30345906.
      Citations: 1763     Fields:    Translation:HumansCTClinical Trials
    29. Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN, Friberg LE. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. Clin Pharmacol Ther. 2019 02; 105(2):486-495. PMID: 30058723; PMCID: PMC6704358.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    30. Lukas RV, Rodon J, Becker K, Wong ET, Shih K, Touat M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J, Fassò M. Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018 Nov; 140(2):317-328. PMID: 30073642.
      Citations: 79     Fields:    Translation:HumansCTClinical Trials
    31. Wongchenko MJ, McArthur GA, Larkin J, Ascierto PA, Sosman J, Andries L, Kockx M, Hurst SD, Caro I, Rooney I, Hegde PS, Molinero L, Yue H, Chang I, Amler L, Yan Y, Ribas A, Dréno B. Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. Clin Cancer Res. 2017 Sep 01; 23(17):5238-5245. PMID: 28536307.
      Citations: 20     Fields:    Translation:Humans
    32. Kim D, Choi Y, Ireland J, Foreman O, Tam RN, Patel R, Schleifman EB, Motlhabi M, French D, Wong CV, Peters E, Molinero L, Raja R, Amler LC, Hampton GM, Lackner MR, Kabbarah O. Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. PLoS One. 2016; 11(11):e0165856. PMID: 27846280; PMCID: PMC5112874.
      Citations: 1     Fields:    Translation:HumansCells
    33. Wilson TR, Yu J, Lu X, Spoerke JM, Xiao Y, O'Brien C, Savage HM, Huw LY, Zou W, Koeppen H, Forrest WF, Fridlyand J, Fu L, Tam R, Schleifman EB, Sumiyoshi T, Molinero L, Hampton GM, O'Shaughnessy JA, Lackner MR. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. NPJ Breast Cancer. 2016; 2:16022. PMID: 28721382; PMCID: PMC5515335.
      Citations: 13     
    34. Lei YM, Chen L, Wang Y, Stefka AT, Molinero LL, Theriault B, Aquino-Michaels K, Sivan AS, Nagler CR, Gajewski TF, Chong AS, Bartman C, Alegre ML. The composition of the microbiota modulates allograft rejection. J Clin Invest. 2016 07 01; 126(7):2736-44. PMID: 27322054; PMCID: PMC4922695.
      Citations: 43     Fields:    Translation:AnimalsCells
    35. Molinero LL, Yin D, Lei YM, Chen L, Wang Y, Chong AS, Alegre ML. High-Fat Diet-Induced Obesity Enhances Allograft Rejection. Transplantation. 2016 05; 100(5):1015-21. PMID: 27007226; PMCID: PMC4846555.
      Citations: 17     Fields:    Translation:AnimalsCells
    36. Spranger S, Barnes SE, Miller ML, Molinero LL, Locke FL, Gajewski TF, Alegre ML, Evaristo C. Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection. J Immunol. 2016 Apr 01; 196(7):2933-8. PMID: 26903482; PMCID: PMC4799771.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    37. Barnes SE, Wang Y, Chen L, Molinero LL, Gajewski TF, Evaristo C, Alegre ML. T cell-NF-?B activation is required for tumor control in vivo. J Immunother Cancer. 2015; 3(1):1. PMID: 25648675; PMCID: PMC4308877.
      Citations: 25     Fields:    
    38. Kinder JM, Then JE, Hansel PM, Molinero LL, Bruns HA. Long-term repeated daily use of intragastric gavage hinders induction of oral tolerance to ovalbumin in mice. Comp Med. 2014 Oct; 64(5):369-76. PMID: 25402177; PMCID: PMC4236785.
      Citations: 7     Fields:    Translation:Animals
    39. Miller ML, Mashayekhi M, Chen L, Zhou P, Liu X, Michelotti M, Tramontini Gunn N, Powers S, Zhu X, Evaristo C, Alegre ML, Molinero LL. Basal NF-?B controls IL-7 responsiveness of quiescent naïve T cells. Proc Natl Acad Sci U S A. 2014 May 20; 111(20):7397-402. PMID: 24799710; PMCID: PMC4034246.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    40. Keerthivasan S, Aghajani K, Dose M, Molinero L, Khan MW, Venkateswaran V, Weber C, Emmanuel AO, Sun T, Bentrem DJ, Mulcahy M, Keshavarzian A, Ramos EM, Blatner N, Khazaie K, Gounari F. ß-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med. 2014 Feb 26; 6(225):225ra28. PMID: 24574339; PMCID: PMC4020714.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    41. Molinero LL, Cubre A, Mora-Solano C, Wang Y, Alegre ML. T cell receptor/CARMA1/NF-?B signaling controls T-helper (Th) 17 differentiation. Proc Natl Acad Sci U S A. 2012 Nov 06; 109(45):18529-34. PMID: 23091043; PMCID: PMC3494911.
      Citations: 34     Fields:    Translation:AnimalsCells
    42. Alegre ML, Molinero LL. The inside story of dendritic cell immunotherapy. Am J Transplant. 2012 Jun; 12(6):1363-4. PMID: 22642470; PMCID: PMC3933448.
      Citations:    Fields:    Translation:AnimalsCells
    43. Porras DL, Wang Y, Zhou P, Molinero LL, Alegre ML. Role of T-cell-specific nuclear factor ?B in islet allograft rejection. Transplantation. 2012 May 27; 93(10):976-82. PMID: 22437847; PMCID: PMC3535294.
      Citations: 5     Fields:    Translation:AnimalsCells
    44. Molinero LL, Alegre ML. Role of T cell-nuclear factor ?B in transplantation. Transplant Rev (Orlando). 2012 Jul; 26(3):189-200. PMID: 22074783; PMCID: PMC3309102.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    45. Campagna L, Molinero LL, Cerliani JP, Croci DO, Ilarregui JM, Fuertes MB, Nojek IM, Fededa JP, Zwirner NW, Rabinovich GA, Toscano MA, Costas MA. Nuclear factor (NF)-?B controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol. 2011 Sep; 48(15-16):1940-9. PMID: 21689853.
      Citations: 24     Fields:    Translation:HumansCells
    46. Molinero LL, Miller ML, Alegre ML, Evaristo C. High TCR stimuli prevent induced regulatory T cell differentiation in a NF-?B-dependent manner. J Immunol. 2011 Apr 15; 186(8):4609-17. PMID: 21411734; PMCID: PMC3544303.
      Citations: 53     Fields:    Translation:AnimalsCells
    47. Bhorade SM, Chen H, Molinero L, Liao C, Garrity ER, Vigneswaran WT, Shilling R, Sperling A, Chong A, Alegre ML. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation. 2010 Sep 15; 90(5):540-6. PMID: 20628341; PMCID: PMC4737704.
      Citations: 28     Fields:    Translation:HumansCells
    48. Molinero LL, Yang J, Gajewski T, Abraham C, Farrar MA, Alegre ML. CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells. J Immunol. 2009 Jun 01; 182(11):6736-43. PMID: 19454668; PMCID: PMC2830151.
      Citations: 62     Fields:    Translation:AnimalsCells
    49. Molinero LL, Wang Y, Zhou P, Yagita H, Alegre ML. Fas mediates cardiac allograft acceptance in mice with impaired T-cell-intrinsic NF-kappaB signaling. Transpl Int. 2009 Aug; 22(8):845-52. PMID: 19351347; PMCID: PMC4423812.
      Citations: 3     Fields:    Translation:AnimalsCells
    50. Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB, Lesniak MS. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Res. 2008 Jul 15; 68(14):5778-84. PMID: 18632631; PMCID: PMC2553687.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    51. Manicassamy S, Yin D, Zhang Z, Molinero LL, Alegre ML, Sun Z. A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection. J Immunol. 2008 Jul 01; 181(1):513-20. PMID: 18566417; PMCID: PMC2488962.
      Citations: 19     Fields:    Translation:AnimalsCells
    52. Molinero LL, Domaica CI, Rossi LE, Rabinovich GA, Zwirner NW, Fuertes MB, Girart MV, Barrio MM, Mordoh J. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol. 2008 Apr 01; 180(7):4606-14. PMID: 18354183.
      Citations: 41     Fields:    Translation:HumansCells
    53. Qiao G, Li Z, Molinero L, Alegre ML, Ying H, Sun Z, Penninger JM, Zhang J. T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b. Mol Cell Biol. 2008 Apr; 28(7):2470-80. PMID: 18227156; PMCID: PMC2268433.
      Citations: 56     Fields:    Translation:AnimalsCells
    54. Molinero LL, Zhou P, Wang Y, Harlin H, Kee B, Abraham C, Alegre ML. Epidermal Langerhans cells promote skin allograft rejection in mice with NF-kappa B-impaired T cells. Am J Transplant. 2008 Jan; 8(1):21-31. PMID: 18021281; PMCID: PMC2829624.
      Citations: 11     Fields:    Translation:AnimalsCells
    55. Chen L, Wang T, Zhou P, Ma L, Yin D, Shen J, Molinero L, Nozaki T, Phillips T, Uematsu S, Akira S, Wang CR, Fairchild RL, Alegre ML, Chong A. TLR engagement prevents transplantation tolerance. Am J Transplant. 2006 Oct; 6(10):2282-91. PMID: 16970798.
      Citations: 90     Fields:    Translation:AnimalsCells
    56. Fuertes MB, Rossi LE, Zwirner NW, Molinero LL, Domaica CI, Girart MV. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol. 2006 Mar; 67(3):170-82. PMID: 16698439.
      Citations: 12     Fields:    Translation:HumansCells
    57. McNerney ME, Lee KM, Zhou P, Molinero L, Mashayekhi M, Guzior D, Sattar H, Kuppireddi S, Wang CR, Kumar V, Alegre ML. Role of natural killer cell subsets in cardiac allograft rejection. Am J Transplant. 2006 Mar; 6(3):505-13. PMID: 16468959.
      Citations: 47     Fields:    Translation:AnimalsCells
    58. Molinero LL, Toscano MA, Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW, Rabinovich GA, Fuertes MB. Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem. 2004 Dec; 267(1-2):177-85. PMID: 15663199.
      Citations: 23     Fields:    Translation:HumansCells
    59. Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW, Molinero LL, Girart MV, Costas MA. NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol. 2004 Nov 01; 173(9):5583-90. PMID: 15494508.
      Citations: 46     Fields:    Translation:HumansCells
    60. Sundberg EJ, Molinero L, Zwirner NW, Llera AS, Mariuzza RA, Malchiodi EL, De Marzí MC, Fernández MM. Cloning, expression and interaction of human T-cell receptors with the bacterial superantigen SSA. Eur J Biochem. 2004 Oct; 271(20):4075-83. PMID: 15479236.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    61. Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW, Molinero LL. Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol. 2003 Jun; 73(6):815-22. PMID: 12773514.
      Citations: 9     Fields:    Translation:HumansCells
    62. Gruber M, Leoni J, Woscoff A, Zwirner NW, Molinero LL. Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis. Clin Immunol. 2003 Jan; 106(1):50-4. PMID: 12584051.
      Citations: 5     Fields:    Translation:HumansCells
    63. Nojek IM, Molinero L, Coso OA, Costas MA, Franco DL. Osmotic stress sensitizes naturally resistant cells to TNF-alpha-induced apoptosis. Cell Death Differ. 2002 Oct; 9(10):1090-8. PMID: 12232797.
      Citations: 9     Fields:    Translation:HumansCells
    64. Marcos CY, Mirbaha F, Fainboim L, Stastny P, Zwirner NW, Molinero LL. Codominant expression of the polymorphic MICA alloantigens encoded by genes in the HLA region. Eur J Immunogenet. 2002 Aug; 29(4):315-9. PMID: 12121277.
      Citations: 3     Fields:    Translation:Humans
    65. Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW, Molinero LL. Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol. 2002 May; 71(5):791-7. PMID: 11994503.
      Citations: 36     Fields:    Translation:HumansCells
    Molinero's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (378)
    Explore
    _
    Co-Authors (17)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _